The Italy Compounding Pharmacy Market was valued at $155.2 Million in 2025 and projected to reach to $211.2 Million by 2030, representing a compound annual growth rate of 6.4%. Italy's compounding pharmacy market is positioned for sustained growth through 2030, supported by regulatory frameworks that encourage specialized pharmaceutical services and rising healthcare provider adoption of personalized medicine approaches.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Italy's compounding pharmacy market is valued at USD 155.2 million in 2025 and is projected to reach USD 211.2 million by 2030, demonstrating robust expansion driven by personalized medicine adoption.
Italy's market is growing at a CAGR of 6.4% (2025-2030), outpacing the global average of 5.7%, indicating accelerated demand for specialized compounding services within the Italian healthcare ecosystem.
Italy's healthcare system actively supports specialized compounding pharmacy services through favorable regulatory policies, enabling pharmacists to deliver customized pharmaceutical solutions tailored to patient needs.
Increasing patient preference for personalized pharmaceutical solutions in Italy is driving market expansion, with healthcare providers recognizing the clinical and economic benefits of customized compounding services.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | HORMONE REPLACEMENT THERAPIES (Therapeutic Application) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 5.7% from 2025 to 2030 |
| Largest Segment | PHARMACEUTICAL DOSAGE ALTERATION (Compounding Type) |
| Market Size Base Year (Billions) | ~USD 14.71 (2025) |
| Revenue Forecast (Billions) | ~USD 19.41 (2030) |
| Segments Covered | Product, Compounding Type, Therapeutic Application |
3 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BAXTER | United States | Public Company | Medical Products & Therapies (IV, infusion, parenteral nutrition, renal-related therapies),Healthcare Systems & Technologies (smart beds, monitoring, OR integration, surgical equipment),Pharmaceuticals (generic and specialty injectables, inhaled anesthetics, compounding services), |
| FAGRON | Belgium | Public Company | Essentials (APIs, excipients, bases),Brands (derma, immunology, hair, scar care),Compounding Services, |
Baxter is a publicly traded American healthcare company founded in 1931 that employs 37,500 people. The company operates as a major medical device and pharmaceutical manufacturer serving global markets.
Fagron is a publicly traded Belgian pharmaceutical company founded in 1990 with 4,880 employees. The company focuses on pharmaceutical compounding and specialty pharmacy solutions.
Italy's compounding pharmacy market is valued at USD 155.2 million in 2025 and is projected to grow to USD 211.2 million by 2030.
Italy's compounding pharmacy market is expected to grow at a CAGR of 6.4% from 2025 to 2030, exceeding the global average.
Key drivers include Italy's aging demographic, rising chronic disease prevalence, increased demand for personalized medications, and supportive EU regulatory frameworks.
Italy's 6.4% CAGR outpaces the global compounding pharmacy market CAGR of 5.7%, reflecting stronger regional demand for customized pharmaceutical solutions.
Pediatric, geriatric, and specialty care patients in Italy benefit most from compounding pharmacies due to personalized dosage forms and tailored therapeutic solutions.
This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global compounding pharmacy market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives of major market companies, and industry consultants, to obtain and verify critical qualitative and quantitative data and evaluate the market's growth prospects. The global market size estimated through secondary research was then validated and refined with inputs from primary research to determine the final market size.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the compounding pharmacy market. The secondary sources used for this study include US Food and Drug Administration (FDA), American Pharmacists Association (APhA), International Academy of Compounding Pharmacists (IACP), National Community Pharmacists Association (NCPA), Parenteral Drug Association (PDA), American Society of Health-System Pharmacists (ASHP), Pharmacy Compounding Accreditation Board (PCAB), European Directorate for the Quality of Medicines & HealthCare (EDQM), European Medicines Agency (EMA), International Pharmaceutical Federation (FIP), Journal of Compounding & Specialty Pharmacy (JCSP), National Center for Biotechnology Information (NCBI), Pharmaceutical Research and Manufacturers of America (PhRMA), Pharma & Biopharma Outsourcing Association (PBOA), World Journal of Pharmaceutical Research (WJPR). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
After an initial assessment of the global compounding pharmacy market landscape through secondary research, comprehensive primary research was conducted. This included in-depth interviews with market experts from the demand side, such as stakeholders from pharmaceutical and biotechnology companies, CROs, CMOs, and academic and research institutions. Additionally, interviews were held with key supply-side participants, including C-suite and senior executives, product managers, and marketing and sales leaders from leading manufacturers, distributors, and channel partners. The research covered six major regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. About 70% of the primary interviews involved supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand market dynamics comprehensively.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Both bottom-up and top-down approaches were used to estimate and validate the total size of the compounding pharmacy market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After estimating the market size using the process described above, the total market was divided into several segments and subsegments. To finish the overall market analysis and obtain precise statistics for all segments and subsegments, data triangulation and market breakdown methods were used where applicable. The data was triangulated by examining various factors and trends from both the demand and supply sides.
A compounding pharmacy is a practice in which a licensed pharmacist combines, mixes, or alters the ingredients of a drug to create a medication tailored to the needs of an individual patient.
Full forecast, segment splits, and company analysis for all Compounding Pharmacy Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report